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Human chromosomal fragile sites are regions of the
genome that are prone to DNA breakage, and are
classiﬁed as common or rare, depending on their frequency
in the population. Common fragile sites frequently
coincide with the location of genes involved in carcino-
genic chromosomal translocations, suggesting their role in
cancer formation. However, there has been no direct
evidence linking breakage at fragile sites to the formation
of a cancer-speciﬁc translocation. Here, we studied the
involvement of fragile sites in the formation of RET/PTC
rearrangements, which are frequently found in papillary
thyroid carcinoma (PTC). These rearrangements are
commonly associated with radiation exposure; however,
most of the tumors found in adults are not linked to
radiation. In this study, we provide structural and
biochemical evidence that the RET, CCDC6 and NCOA4
genes participating in two major types of RET/PTC
rearrangements, are located in common fragile sites
FRA10C and FRA10G, and undergo DNA breakage
after exposure to fragile site-inducing chemicals. More-
over, exposure of human thyroid cells to these chemicals
results in the formation of cancer-speciﬁc RET/PTC
rearrangements. These results provide the direct evidence
for the involvement of chromosomal fragile sites in the
generation of cancer-speciﬁc rearrangements in human cells.
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Introduction
Cancer development can be initiated by the accumula-
tion of various genetic abnormalities that lead to the
disregulation of genes involved in various cellular
processes. Chromosomal translocations are one of such
abnormalities commonly seen in cancer cells. Transloca-
tions result in the rearrangement of genetic material,
which typically leads to the expression of an oncogenic
fusion protein contributing to the neoplastic process
(Gasparini et al., 2007). To date, there are a total of 705
known recurrent translocations in cancer that involve
459 different gene pairs, and are present in many
different types of cancer (Mitelman et al., 2008).
In all translocations, the development of breaks in
DNA strands must occur. There are various ways in
which a cell can acquire these breaks, such as ionizing
radiation (Weterings and Chen, 2008). DNA breaks are
commonly repaired by two pathways, homologous
recombination or non-homologous end joining
(Shrivastav et al., 2008), but dysfunction of these
pathways can contribute to the formation of chromo-
somal translocations (Gasparini et al., 2007). Alterna-
tively, an overwhelming accumulation of DNA breaks
could prevent these normally functioning pathways
from eliminating all of the breaks, leading to transloca-
tion events.
Chromosomal fragile sites are known to contribute to
the formation of DNA breaks and are hotspots for sister
chromatin exchange (Glover and Stein, 1987), chromo-
somal translocations, deletions (Glover and Stein, 1988)
and viral integrations (Popescu, 2003). Fragile sites are
non-random speciﬁc loci that are stable under normal
conditions, but on certain culture conditions can form
visible gaps or breaks in metaphase chromosomes
(Durkin and Glover, 2007). Depending on their
frequency in the population, fragile sites can be divided
into two classes: common and rare. Common fragile
sites, which constitute the majority of the two classes,
are present in all individuals, and are a normal
component of chromosome structure (Glover, 2006).
Common fragile sites can be further classiﬁed based on
their mode of induction, as not all sites are induced by
the same compounds, or to the same extent. Aphidicolin
(APH) induces expression of the majority of common
fragile sites. Other known fragile site-inducing condi-
tions include the addition of 5-bromodeoxyuridine
(BrdU), 5-azacytidine and distamycin A and the
removal of folic acid (Sutherland, 1991). Also, certain
dietary and environmental factors have been shown to
contribute to fragile site expression, including caffeine
(Yunis and Soreng, 1984), ethanol (Kuwano and Kajii,
1987), hypoxia (Coquelle et al., 1998) and pesticides
(Musio and Sbrana, 1997). Together, genetic inﬂuences
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on fragile site instability, along with external inﬂuences
from chemical, dietary and environmental factors,
suggest a possible role for fragile sites in sporadic
cancer formation.
Fragile sites are also known to be late replicating
regions of the genome. Delayed DNA replication has
been observed in all fragile sites examined to date
(Hansen et al., 1997; Wang et al., 1999; Handt et al.,
2000; Hellman et al., 2000, 2002; Palakodeti et al., 2004;
Pelliccia et al., 2008). Delayed replication at fragile
sites is believed to be attributed to the high propensity
of DNA sequences to form stable secondary DNA
structures (Gacy et al., 1995; Usdin and Woodford, 1995;
Samadashwily et al., 1997; Hewett et al., 1998;
Mishmar et al., 1998; Zlotorynski et al., 2003; Zhang
and Freudenreich, 2007). Difﬁculties in passing the
replication fork, caused by secondary DNA structure
formed within the fragile DNA regions, could result in
stalled replication. ATR, a major replication checkpoint
protein, is crucial for maintaining fragile site stability
(Casper et al., 2004), and its inhibition by 2-aminopurine
(2-AP) in conjunction with fragile site-inducing chemicals
signiﬁcantly increases common fragile site expression
(Casper et al., 2002). Therefore, it is suggested that DNA
breakage at fragile sites results from delayed replication
forks that escape the ATR-mediated checkpoint pathway
(Durkin and Glover, 2007).
Many studies point towards the association between
fragile sites and formation of cancer-speciﬁc transloca-
tions (Arlt et al., 2006). In a comprehensive survey, we
found that 52% of all known recurrent simple chromo-
somal translocations have at least one gene located
within a fragile site, strongly suggesting a potential role
for fragile sites in the initiation of translocation events
(Burrow et al., 2009). Also, Glover and colleagues found
that on addition of APH, submicroscopic deletions
within FHIT, located in the fragile site FRA3B and
associated with various human cancers, were detected
and resembled those seen in cancer cells (Durkin et al.,
2008). However, there has been no direct evidence
linking breakage at fragile sites to the formation of
cancer-causing chromosomal aberrations.
Genes participating in the two main types of RET/
PTC rearrangements, RET/PTC1 and RET/PTC3, have
been mapped to known fragile sites (Burrow et al.,
2009). RET/PTC rearrangements are commonly found
in the papillary thyroid carcinomas (PTC), and in all
cases result in the fusion of the tyrosine kinase domain
of RET to the 50 portion of various unrelated genes
(Nikiforov, 2008). In the case of the RET/PTC1 and
RET/PTC3, RET is fused with CCDC6 and NCOA4,
respectively (Santoro et al., 2006). These rearrangements
result in the expression of a fusion protein possessing
constitutive tyrosine kinase activity, which is tumori-
genic in thyroid follicular cells (Nikiforov, 2008). Both
genes involved in the RET/PTC3 rearrangement, RET
and NCOA4, are located at 10q11.2 within fragile site
FRA10G, a common fragile site induced by APH. The
CCDC6 gene, involved in RET/PTC1, is located at
10q21.2 within the fragile site FRA10C, a common
fragile site induced by BrdU. Major breakpoint cluster
regions for these genes have been identiﬁed, and are
located within intron 11 of RET, intron 5 of NCOA4
and intron 1 of CCDC6 (Smanik et al., 1995; Nikiforov
et al., 1999). RET/PTC rearrangements are known to be
associated with radiation exposure, although most of
adult tumors are sporadic and those patients lack the
radiation exposure history (Nikiforova and Nikiforov,
2008), implying that other mechanisms should be
responsible for DNA breakage and RET/PTC forma-
tion in most tumors. Clinical studies have shown that
RET/PTC3 rearrangements are common in radiation-
induced tumors (Fugazzola et al., 1995; Nikiforov et al.,
1997; Motomura et al., 1998). In contrast, sporadic PTC
tumors have shown a greater prevalence of RET/PTC1
rearrangements (Fenton et al., 2000), which account for
70% of all RET/PTC tumor types (Nikiforova and
Nikiforov, 2008). As the participating genes colocalize
with fragile sites and there is a well-established associa-
tion between RET/PTC rearrangements and DNA
damage induced by ionizing radiation, these rearrange-
ments offer an excellent model to examine directly the
role of fragile sites in the formation of cancer-speciﬁc
chromosomal translocations.
In this study, we show that fragile site-inducing
chemicals can create DNA breaks within the RET/PTC
partner genes and ultimately lead to the formation of
RET/PTC rearrangements, offering direct evidence for
the role of fragile sites in cancer-speciﬁc translocations.
Results
Chromosomal disruptions in RET/PTC gene partners
on fragile site induction
To examine whether chromosomal regions involved in
RET/PTC rearrangements are part of fragile sites,
HTori-3 human thyroid cells were exposed to APH,
APHþ 2-AP and BrdUþ 2-AP. Metaphase spreads of
cultured HTori-3 cells were hybridized with ﬂuores-
cently labeled BAC probes covering the entire genomic
sequence of RET, NCOA4 and CCDC6 (Figure 1).
Without exposure to fragile site-inducing chemicals,
metaphase chromosomes of HTori-3 cells seemed
normal with smooth contours and intact RET signal
(Figure 1a). With exposure to fragile site-inducing
chemicals, the morphology of metaphase chromosomes
seemed distorted with irregular surfaces and loss of
continuity. After treatment with 0.4 mM APH for 24 h,
RET was disrupted in 6±0.35% of chromosomes
(Figure 1b and Table 1), NCOA4 was disrupted in
0.62% of chromosomes and no breaks were identiﬁed in
the CCDC6 gene (Table 1). The appearance of breaks
in RET but not in CCDC6 is consistent with the
characteristics of the fragile sites in which each of these
genes are located (RET located at APH-induced
FRA10G and CCDC6 at BrdU-induced FRA10C).
The frequency of breakage observed in RET is in
agreement with the previously published levels at
FRA10G obtained using Giemsa-stained chromosomes,
which were found to be at 4.6% on an average after
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treatment of human skin ﬁbroblasts with 0.2 mM APH
for 26 h (Murano et al., 1989). After addition of APH
and 2-AP, 5.93±0.52% of chromosomes showed breaks
in RET; 0.63±0.08 % showed breaks in NCOA4 and
0.98±0.58% showed breaks in CCDC6. 2-AP is a
general inhibitor of ATR kinase and is known to
increase fragile site expression with or without the
addition of replication inhibitors like APH (Casper
et al., 2002). Although breakage in RET and NCOA4
did not change signiﬁcantly, breakage was now seen in
CCDC6, consistent with 2-AP action. Treatment with
BrdU and 2-AP resulted in 2.72±0.78% of chromo-
somes showing breaks in CCDC6 (Figure 1c). However,
RET and NCOA4 were each disrupted in 0.6±0.08% of
chromosomes after BrdU and 2-AP treatment (Table 1).
Increased breakage in CCDC6 is consistent with its
fragile site mode of induction. Also, the level of
breakage at CCDC6 is comparable with previous
reports at FRA10C, with DNA breakage ranging from
4–20% after treatment of human blood lymphocytes
from 10 patients with 50mg/l BrdU for 4–6 h (Suther-
land et al., 1985). The breakage frequency seen in RET
and NCOA4 with BrdU and 2-AP treatment is similar to
that observed in CCDC6 after treatment with APH and
2-AP, showing consistency with 2-AP-induced breakage.
In concert, these results show directly that chemicals
known to result in fragile site breakage cause DNA
breaks within genomic sequences of genes participating
in RET/PTC rearrangements.
Figure 1 Fluorescence in situ hybridization on metaphase chromosomes of HTori-3 cells after treatment with fragile site-inducing
chemicals. (a) Negative control without treatment showing smooth chromosomes with intact RET (red) signal. (b) Exposure to APH
resulting in irregular chromosome contours and one RET signal (red) showing split in the signal whereas four other RET signals are
intact. Centromeric probe for chromosome 10 is labeled in green. (c) Exposure to BrdUþ 2-AP resulting in the disruption of CCDC6
(green) whereas NCOA4 is intact (red). (d) Exposure to APHþ 2-APþBrdU resulting in split in RET (red).
Table 1 Percentage of chromosomes showing disruption of RET,
NCOA4 and CCDC6 after exposure to fragile site-inducing agents
APH APHþ 2-AP BrdUþ 2-AP
RET 6.00±0.35 5.93±0.52 0.60±0.08
NCOA4 0.62 0.63±0.08 0.60±0.08
CCDC6 0 0.98±0.58 2.72±0.78
Abbreviation: APH, Aphidicolin.
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Induction of DNA breaks in intron 11 of the RET gene
by APH treatment
All RET/PTC rearrangements involve the fusion of the
tyrosine kinase domain of RET, and the major break-
point cluster region identiﬁed in tumor cells is located
within intron 11 (Smanik et al., 1995). Although
ﬂuorescence in situ hybridization (FISH) experiments
allowed us to detect breaks occurring within the RET
gene sequence, whether or not the breaks are located in
intron 11 was next examined using ligation-mediated
PCR (LM–PCR). HTori-3 cells were treated with APH
for 24 h, and the genomic DNAs from both the treated
and untreated cells were subjected to primer extension
with biotinylated primers that are speciﬁc to the regions
of interest (see Materials and methods; Supplementary
Figure 2). The synthesis reaction terminated at a DNA
break to produce a duplex with a blunt end, and the
duplex was ligated to a linker. The linker-attached
DNAs were then isolated by streptavidin beads,
ampliﬁed by two rounds of PCR, and visualized by
agarose gel electrophoresis (Figure 2). Each lane on the
agarose gel represents the DNA breaks isolated from
approximately 4000 cells, and each band observed on
the gel corresponds to a break found within the region
of interest. DNA breaks were observed within intron 11
of RET after treatment with APH (Figure 2a) with a
frequency of 0.024±0.015 breaks per 100 cells, which
was signiﬁcantly higher than that in the untreated cells
(0.004±0.009 per 100 cells, P¼ 0.010; Figure 2b). DNA
samples from lanes 1 and 3–6 in Figure 2a (marked with
asterisks) were sequenced to determine the location of
the induced breakpoints in the RET gene (Figure 3).
DNA sequencing revealed the breakpoints to be located
within intron 11, and at a distance from exon 12 that is
consistent with the size of the PCR product observed on
the agarose gel in Figure 2a. The locations of these
breakpoints were compared with the location of known
breakpoints found in PTC tumors containing RET/PTC
rearrangements (Figure 3) (Bongarzone et al., 1997;
Klugbauer et al., 2001). Each induced breakpoint was
found to be located near a human tumor breakpoint,
with distances ranging from 2–15 base pairs. It is
important to note that these induced breakpoints were
detected before a rearrangement event, whereas the
breakpoints found in tumors have been identiﬁed after a
rearrangement event has occurred. In most cases, small
modiﬁcations, such as deletions and insertions of 1–18
nucleotides, have been observed surrounding the fusion
points in human tumors. These results conﬁrm that the
exposure of thyroid cells to APH induces the formation
of DNA breaks within the major breakpoint cluster
region found in the RET gene, and these induced
breakpoints are located close to known breakpoints
found in human tumors.
DNA breaks were also examined within FRA3B after
APH treatment. FRA3B is the most inducible fragile site
Figure 2 LM–PCR detection of breaks formed in HTori-3 cells after treatment with APH. LM–PCR detection of DNA breaks
formed in HTori-3 cells at intron 11 of RET (a), the fragile site FRA3B (c) and the non-fragile 12p12.3 region (d) after treatment with
APH. The same reaction was carried out as in (a) for intron 11 of RET, but using DNA from cells without APH treatment (b). Last
lane of each gel is a 100 bp molecular weight ladder. Bands below 100 bp correspond to primer dimers. Asterisks mark DNA fragments
that were sequenced, and results are shown in Figure 3.
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in the human genome and contains FHIT, a gene
involved in several cancers, where microscopic deletions
have been observed after treatment with APH (Wang
et al., 1999; Durkin et al., 2008). Intron 4 of the FHIT
gene, a major region of high instability in various
tumors and APH-treated cells (Boldog et al., 1997;
Corbin et al., 2002), was examined for DNA breaks.
DNA breaks were detected within intron 4 of FHIT
on APH treatment (Figure 2c) at a frequency of
0.036±0.020 breaks per 100 cells, conﬁrming that
indeed the APH treatment can induce fragile site
breakage. An increased number of breaks were observed
within FRA3B in comparison to RET, which is
consistent with FRA3B being the most active fragile
site in the genome. A non-fragile region, 12p12.3
(Zlotorynski et al., 2003) and the G6PD gene, within
FRAXF (a rare folate-sensitive fragile site not induced
by APH), were examined after treatment with APH, and
in contrast to RET and FRA3B, no DNA breaks were
observed within the 12p12.3 region (Figure 2d) or in
exon 1 of G6PD (Supplementary Figure 3). The absence
of breaks in 12p12.3 and G6PD suggests that the DNA
breaks observed within RET and FRA3B after exposure
to fragile site-inducing chemicals are because of their
fragile nature in response to APH.
Generation of RET/PTC rearrangements after treatment
with fragile site-inducing chemicals
To test for the induction of RET/PTC rearrangement
after exposure to fragile site-inducing chemicals, HTori-
3 cells were treated with APH and 2-AP for 24 h with the
addition of BrdU for 5 h. These treatment conditions
were chosen because they have been previously estab-
lished to be optimal for the induction of fragile sites
FRA10C and FRA10G (Sutherland et al., 1985;
Murano et al., 1989). To conﬁrm breakage in the genes
after exposure, metaphase spreads were made and
chromosomes were scored for disruption of the probe
(Figure 1d). The breakage in the probes for RET,
NCOA4 and CCDC6 were 7.47, 1.15 and 2.87%,
respectively. The mRNA was then isolated and used in
RT–PCR for detection of RET/PTC1 and RET/PTC3
formation. To assure that a cell with the rearrangement
would be detected, 1 106 cells in a 10 cm culture dish
were divided among 30 culture dishes 24 h post-
exposure. Therefore, each well received no more than
3 104 cells, and if a dish contained only one cell with
RET/PTC, it would constitute one part in 3 104, a
fraction within the limit of detection (Caudill et al.,
2005). No RET/PTC rearrangement was detected with-
out any treatments in ﬁve independent experiments
(Figure 4), indicating an extremely low level of
spontaneous generation of RET/PTC in this human cell
line and the absence of contamination. Similarly, no
RET/PTC rearrangement was detected using the same
experimental approach in HTori-3 cells in four inde-
pendent experiments in a study reported by Caudill et al.
(2005). Exposure to a combination of APH, 2-AP and
BrdU resulted in the generation of RET/PTC1, with ﬁve
total events identiﬁed in ﬁve independent experiments,
each assaying 106 cells (incidence of 2, 1, 2, 0, 0 events
per 106 cells) (Figure 4b). However, no RET/PTC3
rearrangements were identiﬁed. Representative RT–
PCR blots are shown in Figure 4a. Statistical analysis
revealed a signiﬁcant difference in the incidence of RET/
PTC1 induction between untreated cells (zero events)
and cells treated with fragile site-inducing agents (ﬁve
total events) (P¼ 0.027). These results show that the
exposure of thyroid cells to fragile site-inducing
chemicals can lead to the formation of a carcinogenic
RET/PTC rearrangement.
Figure 3 Location of breakpoints within intron 11 of RET induced by treatment with APH. (a) DNA samples from lanes 1, and 3–6
in Figure 2a (marked with asterisks) were sequenced, and six breakpoints are identiﬁed and indicated by black arrowheads. The
locations of known breakpoints found in tumors containing RET/PTC rearrangements are indicated by gray arrowheads (Bongarzone
et al., 1997; Klugbauer et al., 2001). The gray arrow corresponds to the RET-7 primer with a dual biotin label (gray circles), which is
annealed to exon 12 of the RET gene. The black solid and dashed arrows correspond to the RET-R1b and RET-R1 nested
PCR primers, respectively. The sequence of intron 11 is italicized. (b) The distance of each induced breakpoint from the 50 end of the
RET-R1 primer and the nearest patient tumor breakpoint was listed.
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Discussion
Chromosomal rearrangements contribute to the develop-
ment of many types of human tumors. Therefore, it is
critical to understand the mechanisms of chromosomal
rearrangements in cancer cells. Here, we showed that
DNA breakage at fragile sites FRA10C and FRA10G
under fragile site-inducing conditions initiates and leads
to the generation of RET/PTC1 rearrangement, which is
known to contribute to PTC development. To our
knowledge, this is the ﬁrst demonstration that a cancer-
speciﬁc rearrangement can be produced in human cells
by inducing DNA breaks at fragile sites. Interestingly,
only RET/PTC1 rearrangements were observed, and no
RET/PTC3 rearrangements were identiﬁed. Although
breakage was seen within NCOA4, the RET/PTC3
partner gene, the frequency of breakage was lower when
compared with RET and CCDC6. NCOA4 breakage
remained relatively constant with each combination of
fragile site-inducing chemicals, and was about 10-fold
lower than the breakage observed within RET, and
about 4.5-fold below the level found in CCDC6. The
lower incidence of breakage within NCOA4 could
contribute to the lack of RET/PTC3 rearrangement
events. Also, clinical studies have revealed that RET/
PTC3 rearrangements are frequent in radiation-induced
tumors (Fugazzola et al., 1995; Nikiforov et al., 1997;
Motomura et al., 1998), whereas RET/PTC1 rearrange-
ments are more commonly seen in sporadic tumors
(Fenton et al., 2000). Our observation of RET/PTC1
rearrangement, but not RET/PTC3 rearrangement,
generated by fragile site induction, further supports
the idea that sporadic PTC tumors may result from
breakage at fragile sites. It is known that speciﬁc
environmental and food toxins (such as caffeine, alcohol
and tobacco) (Yunis and Soreng, 1984; Kuwano and
Kajii, 1987), and other stress factors (such as hypoxia)
(Coquelle et al., 1998) can induce fragile sites. Therefore,
our results suggest that these exogenous factors may
contribute to the occurrence of chromosomal rearrange-
ments, and therefore cancer initiation in human
populations, by a mechanism of DNA breakage at
fragile sites.
To show that fragile site-inducing chemicals can cause
DNA breaks at RET/PTC participating genes, FISH
analysis of chromosome 10, and LM–PCR analysis at
the nucleotide level of the RET gene were performed.
Using FISH, we showed that on exposure of human
thyroid cells to fragile site-inducing chemicals, chromo-
somal breaks are formed within the RET and CCDC6
genes. RET and CCDC6 are located respectively within
the APH and BrdU-induced fragile sites, and show
breakage only after the addition of APH or BrdU,
accordingly. These results not only show that the
fragility is indeed present within the genes involved in
RET/PTC rearrangements, but also underline the
speciﬁcity of fragile site induction that was observed in
these regions. Although 2-AP addition is known to
increase overall chromosomal breakage and fragile site
FRA3B expression (Casper et al., 2002), no signiﬁcant
increase in breakage at RET and NCOA4 genes was
noted in HTori-3 cells, indicating its weaker inﬂuence on
the FRA10G site. Furthermore, the addition of 2-AP in
combination with APH resulted in the appearance of
breaks within CCDC6, whereas its combination with
BrdU resulted in breaks within RET and NCOA4. This
nonspeciﬁc effect of 2-AP on induction of DNA breaks
at fragile sites is in agreement with its ability to inhibit
ATR protein, which provides a key maintenance role in
fragile site stability.
The DNA breaks generated in RET after exposure to
APH were conﬁrmed to be located within intron 11,
which is the breakpoint cluster region identiﬁed in
thyroid tumors, whereas untreated cells showed little to
no breaks. These breaks are further conﬁrmed to be
fragile in nature, when comparing the formation of
breaks within FRA3B, 12p12.3 and G6PD regions.
FRA3B, the most inducible fragile site in the human
genome (Wang et al., 1999; Durkin et al., 2008), showed
DNA breaks after treatment with APH (Figure 2c),
whereas 12p12.3, a non-fragile region, and the G6PD
gene, located within a rare folate-sensitive fragile site,
showed no DNA breakage with the same treatment
(Figure 2d and Supplementary Figure 3b). Together
with cytogenetic analysis, these results show that fragile
site-inducing chemicals can generate breaks within RET
Figure 4 Detection of RET/PTC rearrangements in HTori3 cells after treatment with fragile site-inducing chemicals. (a) Detection of
RET/PTC rearrangements in representative RT–PCR experiment after exposure to APHþ 2-APþBrdU. (PC, positive control).
(b) Number of rearrangement events detected in untreated cells and cells exposed to APHþ 2-APþBrdU. Five independent
experiments were carried out for each treatment, and each experiment analyzed 106 cells.
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and CCDC6 genes, which could result in the formation
of cancer-causing RET/PTC1 rearrangement.
The induction rate of RET/PTC rearrangement by
fragile site-inducing chemicals was four magnitudes
lower than the frequency of chromosomal breaks
observed in RET and CCDC6 genes. DNA breaks, a
serious threat to genome stability and cell viability, can
trigger DNA repair pathways, including homologous
recombination or non-homologous end joining (Shri-
vastav et al., 2008). The action of these pathways
ensures proper repair of DNA breaks, and prevents the
deleterious consequences of such breakage. However,
some (small number of) DNA breaks escaping the repair
pathways will ultimately result in large-scale chromo-
somal changes, such as RET/PTC rearrangement.
This study provides important information about the
mechanisms of formation of carcinogenic chromosomal
rearrangements in human cells. In addition, it estab-
lishes an experimental system that will allow for testing
the role of speciﬁc environmental substances, dietary
toxins and other stress factors in the generation of
chromosomal rearrangements and tumor initiation.
Materials and methods
Cell line and culture conditions
The experiments were performed on HTori-3 cells, which are
human thyroid epithelial cells transfected with an origin-
defective SV40 genome. They are characterized as immorta-
lized, partially transformed, differentiated cells having three
copies of chromosome 10 with intact RET, NCOA4 and
CCDC6 loci and preserve the expression of thyroid differ-
entiation markers, such as thyroglobulin production and
sodium iodide symporter, as we reported previously (Caudill
et al., 2005). The cells were purchased from the European
Tissue Culture Collection and grown in RPMI 1640 medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum.
Fragile site induction
HTori-3 cells (1 106) were plated in 10 cm culture dishes and
after 16 h were exposed to APH for 24 h (0.4 mM) or APH and
2-AP (2mM) (Casper et al., 2002). When desired, cells were
treated with BrdU (50mg/l) for 5 h, in addition to 2-AP and/or
APH for 24 h. For DNA breaksite detection, 5 105 cells were
plated in 10 cm culture dishes and treated in the same manner
as above with 0.4mM APH.
Metaphase chromosome preparation
HTori-3 cells exposed to various chemicals were treated with
0.1 mg/ml of Colcemide for 2 h before harvesting. Cells were
incubated in hypotonic solution (0.075M KCL), ﬁxed in
multiple changes of methanol:acetic acid (3:1) and dropped
onto moistened slides to obtain metaphase spreads. Slides were
aged overnight and pretreated with RNase before proceeding
for hybridization.
Probes for FISH
BAC clones RP11-351D16 (RET), RP11-481A12 (NCOA4),
RP11-435G3 and RP11-369L1 (CCDC6) were obtained
from BAC/PAC Resources, Children’s Hospital, Oakland,
CA, USA. BAC clone RP11-481A12 containing the NCOA4
gene was subcloned into fosmid vector after cutting with
restriction enzymes (Epicenter). A mixture of subcloned
probes (SC10, SC19) containing 70 kb of the NCOA4
gene and its ﬂanking regions was used as a probe for NCOA4.
The probes were labeled by nick translation using Spe-
ctrum Green-dUTP, Spectrum Orange-dUTP or Spectrum
Red-dUTP (Abbott Laboratories, Des Plaines, IL, USA).
Hybridization was performed as previously described (Ciampi
et al., 2005). On average, 150 chromosomes were scored
for breaks in the RET, NCOA4 and CCDC6 probes for
each condition.
DNA breaksite mapping by LM–PCR
To detect DNA breaks within intron 11 of RET induced by
APH, a 50-biotinylated primer RET-7 corresponding to the
RET at the 50 end of exon 12 (the gray arrow in Figure 3a) was
used to extend into intron 11. For ﬁrst and second rounds of
nested PCR primers RET-R1b and RET-R1 were used,
respectively. To isolate the DNA breaks, a duplex DNA linker
LL3/LP2 was used as described (Kong and Maizels, 2001) as
well as the corresponding linker speciﬁc primers LL4 and LL2
(Supplementary Figure 2). For FRA3B, the biotinylated
primer FRA3B-20 was used to allow identiﬁcation of break
sites occurring at intron 4 of the FHIT gene, which contains
major clusters of APH-induced breakpoints in FRA3B
(Boldog et al., 1997; Corbin et al., 2002), and primers
FRA3B-9 and FRA3B-23 were used in ﬁrst and second
rounds of nested PCR, respectively. For detection of breaks
within the 12p12.3 region, the biotinylated primer 12p12.3-1
and primers 12p12.3-2 and 12p12.3-3 were used. For detection
of breaks within exon 1 of G6PD, the biotinylated primer
G6PDF3 and primers G6PDF and G6PDF2 were used.
Sequence of linkers and PCR primers is described in the
Supplementary Figure 1.
DNA breaksite mapping was performed as described (Kong
and Maizels, 2001) with modiﬁcations (Supplementary Figure
2). Genomic DNA was isolated from HTori-3 cells with or
without APH treatment. Primer extension was performed
using 200 ng of DNA at 45 1C, and the DNA breaks were
isolated through ligation of the LL3/LP2 linker, and then
using streptavidin beads. Ampliﬁcation of these DNA breaks
was achieved by nested PCR of the extension–ligation
products. The ﬁnal PCR products were resolved by electro-
phoresis on a 1.3% agarose gel. Each band observed on the gel
corresponds to a break isolated within the region of interest.
To conﬁrm the bands observed were located within intron 11
of RET, the PCR products were sequenced. The exact
breakpoint sites were determined from the sequencing results
by identifying the nucleotide adjacent to the LL3/LP2 linker
sequence.
Detection of RET/PTC rearrangements
Upon treatment with fragile site-inducing agents for 24 h, cells
were split into 30 6 cm culture dishes at a density of
approximately 3 104 cells per dish and grown for 3–4 days.
To sustain growth for 9 days, cells were transferred to 10 cm
culture dishes for 4–5 days after seeding into 6 cm dishes. RNA
was extracted from each culture dish using a Trizol reagent
(Invitrogen). Then, mRNA was puriﬁed using the Oligotex
mRNA minikit (Qiagen, Valencia, CA, USA). RT–PCR was
performed using a Superscript ﬁrst strand synthesis system kit
and random hexamer priming (Invitrogen, ). PCR was
performed to simultaneously detect RET/PTC1 and RET/
PTC3 rearrangement using primers RET/PTC1 forward,
RET/PTC3 forward, and common reverse (Supplementary
Figure 1). As positive controls, cDNA from RET/PTC1-
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positive TPC-1 cells and RET/PTC3 positive tumor sample
were used. Ten micro liter of each PCR product was
electrophoresed in a 1.5% agarose gel, transferred to the
nylon membrane and hybridized with 32P-labeled oligonucleo-
tide probes speciﬁc for RET/PTC1 and RET/PTC3 (Supple-
mentary Figure 1). Evidence of RET/PTC rearrangement in
the cells from a given ﬂask was scored as one RET/PTC event.
All statistics performed using one-tailed Student’s t-test.
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 Supplementary Figure 1 
Linker and Primer Sequences for LM‐PCR 
LL3      5’‐CGAGTTCAGTCCGTAGACCATGGAGATCTGAATTC‐3’ 
LP2      5’‐GAATTCAGATCTCC‐3’ 
LL4      5’‐CGAGTTCAGTCCGTAGAC‐3’ 
LL2      5’‐GTAGACCATGGAGATCTGAAATTC‐3’ 
RET‐7      5’‐ BBCAGCATCTTCACGGCCACCGTGG‐3’ (B, biotin) 
RET‐R1b    5’‐ TACCCTGCTCTGCCTTTCAGATGG‐3’ 
RET‐R1      5’‐AGTTCTTCCGAGGGAATTCC‐3’ 
FRA3B‐20    5’‐ BBCCTATCTGACGACTTCAC‐3’ (B, biotin) 
FRA3B‐9    5’‐ GAAAGCATAAAGTGTGGC‐3’ 
FRA3B‐23    5’‐ TAACTGCTTATTTTTCCGATGT‐3’ 
12p12.3‐1    5’‐ BBTTTTCTTGACTAGTCTAACCAGAT‐3’ (B, biotin) 
12p12.3‐2    5’‐ TTTCACTTGTATTGATCTCCTTCAT‐3’ 
12.12.3‐3    5’‐ TTTCCACTGTTTGCCGCATTAT‐3’ 
G6PDF3    5’‐BBAGTAAAAACACAAGCCCCGCCCC‐3’ (B, biotin) 
G6PDF      5’‐TAGGGCCGCATCCCGCTCCGGAGAGAAGTCT‐3’ 
G6PDF2    5’‐GGCCACTTTGCAGGGCGTCA‐3’ 
 
PCR primers for Detection of RET/PTC Rearrangements 
RET/PTC1 forward  5'‐CAAGAGAACAAGGTGCTGAAG‐3' 
RET/PTC3 forward  5'‐CGGTATTGTAGCTGTCCCTTTC‐3' 
common reverse  5'‐GCAGGTCTCGAAGCTCACTC‐3' 
 
32P‐labeled oligonucleotide probes 
RET/PTC1    5'‐CGTTACCATCGAGGATCCAAA‐3' 
RET/PTC3    5'‐GAACAGTCAGGAGGTCCAA‐3' 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Supplementary Figure 2.  DNA breaksite mapping by LM‐PCR. Genomic DNA was isolated from HTori‐3 
cells with or without APH treatment, and was denatured and then annealed to a biotinylated primer 
specific for the region of interest.  Primer extension was carried out with DNA Sequenase, and the 
reaction terminates at a DNA break.  DNA breaks were isolated through ligation of the LL3/LP2 linker, 
and recovered by streptavidin beads.  Amplification of these DNA breaks was achieved by nested PCR 
of the extension‐ligation products.  The final PCR products were resolved by agarose gel 
electrophoresis.  Each band observed on the gel corresponds to a break found within the region of 
interest.  The exact breakpoint sites were determined by DNA sequencing of the PCR products, and by 
identifying the nucleotide adjacent to the LL3/LP2 linker sequence.  
 
Supplementary Figure 2 
 
 Supplementary Figure 3.    LM‐PCR detection of breaks  formed  in HTori‐3 cells after  treatment with 
APH.  LM‐PCR detection of DNA breaks formed in HTori‐3 cells at  intron 11 of RET (a) and exon 1 of 
G6PD (b) after treatment with APH.  Last lane of each gel is a 100 bp molecular weight ladder. 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